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The overactive bladder is characterized by symptoms of frequency, urgency, and urge incontinence, substantially affecting the
quality of life of millions of people throughout the world. The symptoms are associated with significant social, psychological,
occupational, domestic, physical, and sexual problems. Despite the considerable impact of this condition on quality of life, sufferers
are often unwilling to discuss their problem with family members or health care professionals. This situation is unfortunate, for
much can be done to alleviate the symptoms of this distressing condition. It is therefore of utmost importance that medical education
about symptoms of the overactive bladder and other related problems be improved to help health care professionals identify and treat
patients who will benefit from therapy. This article reviews current thinking regarding definition, epidemiology, quality of life
effects, evaluation, and management of the overactive bladder.
DESCRIPTORS: Bladder diseases. Urinary incontinence. Urodynamics.
The overactive bladder (OAB) is a
highly prevalent disorder that impacts
the lives of millions of people world-
wide. Despite its high prevalence, most
sufferers do not seek medical attention
and are unaware that OAB is treatable.
Notwithstanding the recently increased
medical and media attention given to
it in many countries, OAB remains
vastly underreported and its sufferers
untreated. The purpose of this manu-
script is to update the definition of
OAB for the clinicians involved with
the treatment of patients with voiding
dysfunction and to present a clinically
relevant approach for the evaluation
and treatment of this disorder. Further,
expanded information may be found in
recently published reviews and confer-
ence proceedings1-3.
SYMPTOMS AND DEFINITION
Typical symptoms of the overactive
bladder include an increased number of
micturitions (frequency—emptying the
bladder more often than 8 times a day),
a strong and sudden desire to void (ur-
gency), and if the urge cannot be sup-
pressed, urinary urge incontinence.
Symptoms of OAB presumably occur
because the detrusor muscle is
overactive and contracts inappropriately
during the filling phase4-7. Frequency
can occur as a result of reduced func-
tional bladder capacity. It can also be
caused at least partly by a coping
mechanism adopted by patients to avoid
leakage of large volumes of urine by
maintaining a relatively low volume in
the bladder. When patients experience a
sensation of urgency, they may leak
urine if they are unable to reach the toi-
let quickly or if the sensation of urgency
is very strong. The amount of urine lost
may be large, since the bladder may
empty completely. Sleep may be dis-
turbed, since the need to void may be
experienced during the night. Nighttime
frequency and nocturnal enuresis
(bedwetting) is often particularly disrup-
tive. When bladder contraction occurs
without warning and sensation is absent,
as in a patient with neurologic disease
such as spinal cord injury, the condition
is referred to as reflex incontinence.
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The definition of the overactive
bladder by the International Conti-
nence Society (ICS) is based on
urodynamics and is currently being re-
evaluated6,8,9. The ICS definition in-
cludes the presence of involuntary
bladder contractions that are provoked
during a filling cystometrogram while
the patient is attempting to suppress
them8. The reasons why the definition
must be changed are twofold: (1) on a
worldwide basis, it is impractical, un-
necessary, and impossible for all pa-
tients with symptoms of bladder
overactivity to be treated by urologists
and undergo urodynamic studies, a
necessary step in the diagnosis of this
condition based on the present defini-
tion of the ICS, and (2) urodynamic
studies can have both false-positive and
false-negative results, and these mis-
taken test results can include normal
patients in the diagnosis of bladder
overactivity or exclude patients who
clearly have overactive bladder symp-
toms based on a false-negative
urodynamic study.
It should be possible to define blad-
der overactivity based on symptoms3.
A reasonable symptom-based defini-
tion would be a condition referring to
the symptoms of frequency and ur-
gency, with or without urge or reflex
incontinence, when appearing in the
absence of local pathological factors
(e.g. cancer, carcinoma-in-situ, urinary
tract infection, stones, interstitial cys-
titis) as explanations for these symp-
toms. Patients with overactive bladder
can include individuals with and with-
out a possible neurologic cause for
their symptoms. Urodynamic bladder
overactivity would then describe the
phenomenon of involuntary bladder
contractions causing symptoms or
signs. The distinction between detrusor
hyperreflexia and instability is not as
clear-cut as it once seemed, however.
Does an individual with involuntary
bladder contractions with no gross neu-
rological signs or symptoms but with
a cerebral imaging abnormality have
hyperreflexia or instability? Does it
matter?
PREVALENCE
It is difficult to estimate the true
prevalence of bladder overactivity for
two reasons: (1) Despite the consider-
able impact of bladder storage symp-
toms on quality of life, many patients
never seek medical help and are thus
uncounted; (2) There have been very
few epidemiologic surveys carried out
on the symptoms of urgency and fre-
quency alone without incontinence.
Surveys on the prevalence of urinary
incontinence have been done, and es-
timates of the prevalence of bladder
overactivity have been obtained by
adding together the fraction of urge in-
continent patients to the number of
those with mixed incontinence6,9,10.
Thus, the most prevalent figures that
are available significantly underesti-
mate the extent of the problem. A re-
cent survey has found that the vast ma-
jority of people with chronic, bother-
some symptoms of bladder overactivity
complained of frequency and urgency,
while only a third complained of urge
incontinence11. The survey found that
the total prevalence of OAB within the
general population aged 40 years and
over ranged from 12% to 22% in a
sample of some 17 000 people in 6 Eu-
ropean countries. It demonstrated that
the risk of developing OAB increases
with age. In the group of people 75
years and older, the prevalence ranged
between 30% and 40%11. Another
problem that one encounters is exactly
how to define urgency and frequency.
For instance, if one defines frequency
as simply voiding over 8 times per day,
one will conclude that an incredible
proportion of the world’s population
has overactive bladder. Furthermore,
most of us experience significant ur-
gency on one occasion or another, but
it is not a chronic problem for us. Thus,
the way that questions are asked re-
garding frequency and urgency makes
a great difference with respect to re-
ported prevalence.
QUALITY OF LIFE; SOCIAL
COSTS
Urinary incontinence is associated
with reduced levels of social and per-
sonal activities, increased psychologi-
cal distress, and overall decreased qual-
ity of life (QOL) as measured by nu-
merous indices12-16. Urinary inconti-
nence is, however, only one aspect of
OAB. Little data exists on the QOL
impact of OAB in general or of ur-
gency and/or frequency without incon-
tinence17.
Emerging studies and studies in
progress have shown that patients with
OAB do suffer significantly poorer
QOL than an age matched popula-
tion11,18. Those with OAB have been
found to experience a lower QOL in
the social and functional domains than
diabetics. Other studies have shown
that the QOL of patients with symp-
toms caused by the overactive bladder
is more adversely affected than that of
stress incontinence sufferers. This find-
ing presumably reflects the differences
in the symptoms experienced. Com-
pared with stress incontinence, the
overactive bladder is harder to predict,
is more likely to disrupt sleep and daily
activities, and more often leads to the
loss of large volumes of urine14,19.
The overactive bladder and stress
incontinence are problems that both
sufferers and their physicians often fail
to discuss. In a survey conducted in the
UK, it has been shown that although
approximately half of all sufferers
would welcome some form of treat-
ment, there is a reluctance to seek
help11. Only one-third of regularly in-
continent women discuss their problem
with a nurse or primary care physician.
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Up to two-thirds of patients first seek-
ing medical advice have had their
symptoms for over 2 years. The rea-
sons cited for this marked reluctance to
seek help include low expectations of
treatment and being too embarrassed.
The medical profession has often
done little to dispel patients’ common
misconceptions about the condition.
Research in this area has shown that
although the majority of patients who
discuss their condition with their pri-
mary care physician feel that they are
treated sympathetically, 30% of those
who discuss their problems with a
health care professional receive no as-
sessment and about 80% are not exam-
ined. Dismissing incontinence and re-
lated symptoms as minor ailments is
misguided.
These symptoms can be the cause
of great discomfort, shame, and loss of
confidence, causing withdrawal from
social life and affecting physical and
mental health. In addition to the nega-
tive impact on the quality of life of
those affected, a considerable financial
burden is placed on society as a result
of neglecting to diagnose and treat the
condition20. Studies of health care costs
in the USA and Sweden estimate that
urinary incontinence accounts for at
least 2% of the national health care
budgets11. Wagner and Hu estimated
that the societal cost of incontinence
for individuals in the USA aged 65
years and older in 1995 was a stagger-
ing 26.3 billion dollars21.
PATHOPHYSIOLOGY
Ultimately, whatever the primary
cause of OAB, the mechanism for
bladder overactivity must be either
neurogenic or myogenic22,23. The cen-
tral nervous system mechanisms con-
trolling the lower urinary tract are or-
ganized in the brain and spinal cord as
simple on-off switching circuits under
voluntary control. Damage to central
pathways that are normally inhibitory
(stroke, Parkinson’s disease, multiple
sclerosis, spinal cord injury, etc.) or
sensitization of peripheral afferent ter-
minals in the bladder can unmask
primitive voiding reflexes that trigger
bladder overactivity. This neurogenic
basis is fully explored by deGroat23.
Brading summarizes evidence for myo-
genic basis for OAB22. She describes
spontaneous contractile (electrical) ac-
tivity in detrusor strips from all species
that is myogenic (originating in the
muscle itself) but that fails to produce
fused tetanic contractions because of
poor electrical coupling between blad-
der smooth muscle cells. Precipitating
factors such as bladder outlet obstruc-
tion can cause a partial denervation of
smooth muscle, leading to a state of
decreased responsiveness to activation
of intrinsic nerves but supersensitivity
to contractile agonists and direct elec-
trical activation24-26. Spontaneous activ-
ity increases, and there is an increase
in cell-to-cell electrical coupling. Fill-
ing, under these circumstances, could
cause synchronous activation of the
smooth muscle of the bladder wall and
an increase in intravesical pressure. The
most plausible situation for this type of
phenomenon to occur would be in the
male with bladder outlet obstruction, a
condition in which 50% of affected in-
dividuals exhibit detrusor instability27-30.
Each theory has its proponents, and
doubtless, neither can account for all in-
stances of OAB. It is often difficult to
separate neurogenic and myogenic ori-
gin, and often they seem to be intercon-
nected and complementary.
EVALUATION
Identifying patients with lower uri-
nary tract symptoms caused by an
OAB, and differentiating between
OAB and other types of urinary incon-
tinence (i.e. stress incontinence, etc) is
paramount to selecting appropriate
treatment for the individual patient.
National and international urological
societies recommend that the initial
evaluation should include, at a mini-
mum (1) an assessment of the patient’s
symptoms; (2) physical examination;
and (3) urinalysis31,32. A holistic ap-
proach should be employed, in which
confounding conditions are identified
and addressed. Once urinary tract in-
fection has been excluded, it is possi-
ble in most cases to establish a work-
ing diagnosis based on the patient’s
description of symptoms and initiate
therapy. In some patients, particularly
those with symptoms of difficulty emp-
tying, it may be desirable to measure
post-void residual urine by catheteriza-
tion or ultrasound to exclude incom-
plete bladder emptying as a cause of
the patient’s symptoms. In cases where
there is uncertainty regarding the diag-
nosis, more advanced investigations,
such as urodynamic assessment and/or
cystoscopy should be carried out.
Symptom Assessment. When tak-
ing the patient’s history, the aim is to
both make a working diagnosis and to
assess the impact of the symptoms on
the patient’s quality of life. As dis-
cussed previously, the typical symp-
toms of OAB include frequency, ur-
gency, and urge incontinence. How-
ever, symptoms are not always diag-
nostic. Patients with stress inconti-
nence, for example, may void fre-
quently in an attempt to avoid leakage,
since this condition is generally worse
when the bladder is full. A careful his-
tory of the condition, with special em-
phasis on onset, progression/regres-
sion, response/nonresponse to treat-
ments, is valuable. The use of a diag-
nostic aid is sometimes helpful for dis-
tinguishing between the symptoms of
OAB and stress incontinence (Table 1).
However, these two conditions often
coexist9. Symptoms of bladder
overactivity can, however, be treated
successfully in women with mixed in-
continence symptoms. The review of
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symptoms should concentrate on fac-
tors potentially related to etiology (neu-
rologic, metabolic, medications, etc).
Frequency of micturition, the sen-
sation of urgency and leakage episodes
can be assessed by patient recall at the
time of interview, or by self-monitor-
ing using a frequency/volume chart or
voiding diary (Fig. 1). Self-monitoring
on a daily basis, using a chart, is a sim-
ple and practical method of obtaining
information on voiding behavior. The
point in time and volume of all voids
over a specified period, together with
subjective information regarding sensa-
tions of urgency and leakage episodes,
are recorded in the individual’s own
environment under normal conditions.
To quantitate the amount of urine loss,
if incontinence exists, a variety of pad
tests are available and can serve as a
baseline for subsequent outcome as-
sessment33.
Physical Examination. Physical
examination should ideally include an
abdominal exam to exclude a distended
bladder, a neurologic assessment of the
perineum and lower extremities, a pel-
vic exam in women (looking especially
for evidence of prolapse or hormonal
deficiency), and a genital and prostate
exam in men. In females, an assess-
ment of anterior vaginal wall prolapse
(i.e. urethral hypermobility) and a
Marshall-Bonney test may be per-
formed to exclude coexistent stress in-
continence in those patients with symp-
toms of mixed urinary incontinence. In
both sexes, digital rectal exam provides
an opportunity to check ambient rec-
tal tone, the integrity of the sacral re-
flex arc (e.g. anal wink, etc.), as well
as to assess the patient’s ability to per-
form a voluntary pelvic floor muscle
contraction (i.e. “Kegel” exercise),
which may be an important factor in
deciding on appropriate therapy.
Urinalysis. Altered bladder sensa-
tion during urinary tract infections can
cause symptoms similar to those of
OAB. Urine microscopy and culture
are the diagnostic gold standard, but
reagent strip testing of urine is a sen-
sitive and cheaper screening method.
Tumors of the lower urinary tract may
likewise cause urgency, frequency, and
urge incontinence. Hematuria merits
further urologic investigation. Irritative
symptoms may prompt a voided urine
sent for cytology, which, if positive for
tumor or dysplastic cells, should like-
wise mandate further urologic evalua-
tion. Significant glucosuria or proteinu-
ria should prompt further medical or
nephrologic evaluation or referral.
Residual Urine Measurement. It
is desirable to measure post-void re-
sidual urine in some patients, particu-
larly in the elderly with voiding symp-
toms and/or recurrent or persistent uri-
nary tract infections, in those with neu-
rological disease and voiding dysfunc-
tion, and in those with symptoms that
suggest poor bladder emptying. Ultra-
sound or catheterization may be used
to measure the volume of urine re-
maining in the bladder after voiding
with distinct advantages to each
method34,35.
Table 1 - Differentiating OAB from stress incontinence (After Abrams and Wein,
1998) 11.
SYMPTOMS Overactive Bladder Stress Incontinence
Urgency (strong, sudden Yes No
desire to void)
Frequency with urgency Yes Rarely
Leaking during physical No Yes
activity e.g., coughing,
sneezing, lifting, etc.
Amount of urinary leakage Large Usually
with each episode of incontinence if present small
Ability to reach the toilet in No or Yes
time following an urge to void just barely
Nocturnal incontinence (presence of Yes Rarely
wet pads or undergarments in bed)
Nocturia (waking to pass urine at night) Usually Seldom
*Stress incontinence is leakage when coughing, sneezing, or with physical activity; urge incontinence is leakage associated with a
strong desire to void that cannot be suppressed, and unaware incontinence is leakage that is not perceived by the patient when it happens.
** large (soaked underwear), medium (damp), or small (few drops)
Figure 1 - Frequency/volume chart or voiding diary to be completed over a 24-hour period, preferably
for 3 to 5 consecutive days.
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Other Studies. Urodynamic stud-
ies quantitate data referable to the ac-
tivity of the bladder and bladder out-
let during the filling/storage and emp-
tying phases of micturition. This tech-
nique allows exact characterization of
any voiding dysfunction as well as the
demonstration of lower urinary tract
obstruction and its secondary effects on
the bladder. A great deal of information
regarding the function of the lower uri-
nary tract is readily available from a
properly performed urodynamic study,
but its interpretation should be made
within the context of the patient’s pre-
senting symptoms. Clearly, not all pa-
tients presenting with complaints of the
OAB require sophisticated or even sim-
ple urodynamics. These studies are
generally reserved for patients with
mixed symptomatology or those who
have failed initial therapy.
 Other studies including cystos-
copy, measurement of serum PSA, se-
rum chemistries, including creatinine
and radiographic imaging, should be
done in a selective and judicious man-
ner when clinically indicated.
MANAGEMENT
Transient or reversible conditions
that result in OAB-type symptoms
should immediately be addressed.
These will be readily identified from a
properly performed history, physical
examination, and initial evaluation as
described previously (e.g. urinary in-
fection, hormone deficiency, drug side
effects, excessive urine output, fecal
impaction, altered mental state). Ap-
propriate treatment of other conditions
that can contribute to or be associated
with OAB (bladder outlet obstruction,
vaginal prolapse, significant stress in-
continence, diabetes) should always be
considered, since therapy of these
problems may often improve or allevi-
ate symptoms completely.
Except in those cases where OAB
is clearly secondary and reversible by
correction of a primary cause (bladder
outlet obstruction, etc.), one does not
cure OAB. One rebalances lower uri-
nary tract function with the help of
behavioral, pharmacologic, neurosti-
mulatory, or surgical modalities. Actual
management options for OAB are
fairly easy to characterize and are de-
signed to facilitate bladder filling/urine
storage by decreasing contractility, in-
creasing capacity, or decreasing sensa-
tion (Table 2). We will consider only
some of these in detail and refer the
reader to other sources for a more com-
plete discussion and references1,2,36-41.
Behavioral therapy
This rubric includes: (1) patient edu-
cation about lower urinary tract func-
tion; (2) fluid management; (3) bladder
training or retraining; (4) pelvic floor
physiotherapy; and (5) for physically or
mentally challenged individuals, sched-
uled and/or prompted voiding. For the
average community-dwelling indi-
vidual, the aim of behavioral therapy is
to help regain bladder control by in-
creasing the effective capacity of the
bladder and thereby reducing the symp-
toms of the overactive bladder. Keeping
a record in the form of a frequency/vol-
ume chart, plays a central role in blad-
der training, as well as looking at the
urine output in relation to the patient’s
fluid intake, which may need to be re-
duced. The patient is asked to gradually
increase the intervals between voiding
by maneuvers that inhibit the micturi-
tion reflex (i.e. pelvic floor exercise or
“Kegel” exercises), resulting in a
gradual increase in bladder capacity.
These exercises are taught in such a way
that patients can use this physiologic
mechanism to inhibit an impending or
beginning bladder contraction (micturi-
tion reflex). A properly timed “Kegel”
exercise (voluntary contraction of the
striated muscle of the pelvic floor) may
have the dual benefit of increasing out-
let resistance as well as inhibiting the
micturition reflex and sacral arc during
an involuntary bladder contraction. Of-
ten patients are initially unable to “find”
and voluntarily contract their pelvic
floor effectively. Biofeedback and/or
electrical stimulation may be quite ben-
eficial as adjunctive measures in ena-
bling patients to locate and utilize their
pelvic floor in an effective manner. The
frequency/volume chart is used through-
out therapy in order to monitor its suc-
cess. Initially, in some cases, it may be
useful to ask the patient to void hourly
by the clock. Once this is managed
without leakage, the interval is increased
by 15 minutes at a time, until the inter-
val between voiding is between 2 and
4 hours.
 Results with behavioral therapy are
quite good. Fantl et al. recorded a 57%
reduction in incontinent episodes and
a 54% reduction in the quantity of
urine loss in older women42. The reduc-
tion in incontinence episodes was simi-
lar in patients with OAB and stress in-
Table 2 - Therapy to facilitate bladder
filling and urine storage.
Inhibiting bladder contractility, decreasing
sensory input and/or increasing bladder
capacity
Behavioral therapy
Timed bladder emptying
Bladder training; biofeedback
Pharmacologic therapy
Anticholinergic agents
Musculotropic relaxants
Calcium antagonists
Potassium channel openers
Prostaglandin inhibitors
Beta-adrenergic agonists
Alpha-adrenergic antagonists
Tricyclic antidepressants
Dimethyl sulfoxide (DMSO)
Polysynaptic inhibitors
Therapy decreasing sensory input
Bladder overdistention
Electrical stimulation (reflex inhibition);
neuromodulation
Acupuncture
Interruption of Innervation
Central (subarachnoid block)
Sacral rhizotomy, selective sacral rhizotomy
Perivesical (peripheral bladder denervation)
Augmentation cystoplasty
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continence; the reduction in quantity of
loss was better in OAB patients than
those with stress incontinence. Fantl
reviewed several studies and concluded
that behavioral therapy for OAB re-
sulted in complete resolution of symp-
toms in less than 15% of patients but
a 50 to 75% reduction of symptoms in
50%43. Behavioral therapy can be uti-
lized by any health care professional.
It is simple, inexpensive, and effective.
It does, however, require patient and
caregiver motivation and a time com-
mitment14,44. It can and should be eas-
ily combined with other nonsurgical
regimens.
Pharmacotherapy
Pharmacotherapy and behavioral
therapy are the mainstays of treatment
of OAB. Although there are multiple
central and peripheral sites and mecha-
nisms that can influence bladder func-
tion, few are clinically useful. The
problems are: (1) how to affect blad-
der function without interfering with
the function of other organ systems
(uroselectivity) and (2) how to elimi-
nate overactivity without disturbing
normal micturition36. Multiple types of
drug therapies are potentially useful for
decreasing bladder contractility or de-
crease sensation, but antimuscarinic
medication remains the most com-
monly prescribed treatment (Table
3)32,39,45.
Parasympathetic impulses travel to
the bladder along the efferent fibers of
the pelvic nerves. Contractions of the
detrusor muscle are mediated mainly
by muscarinic receptors. There are 5
known subtypes of these receptors.
Muscarinic receptors are widely dis-
tributed throughout the body. However,
it is the M-3 variety that is responsible
for involuntary bladder contractions
and for the emptying contraction of a
normal micturition46.
Thus, most antimuscarinic therapy is
primarily anti–M-3 based. Atropine is
the reference anticholinergic compound;
however, it is not readily absorbed from
the GI tract and has the potential to
cause significant adverse effects. Cur-
rently, there are many anticholinergic
preparations available for the phar-
macologic treatment of the OAB. Some
of these pharmaceuticals have an addi-
tional and varying component of direct-
acting smooth muscle relaxant proper-
ties (musculotropic smooth muscle re-
laxant or antispasmodic properties).
Whether these agents exert their clini-
cal effects primarily through an anti-
cholinergic mechanism or by way of a
direct action on smooth muscle is un-
known. In addition, the molecular
mechanism by which these direct-acting
smooth muscle relaxants act is un-
known, but it is generally felt to be
somewhere metabolically distal to the
muscarinic receptor, perhaps in altering
the intracellular handling of calcium.
Several recent reviews cover these
medications and their effects on the
lower urinary tract in more detail39,47. In
patients with involuntary bladder con-
tractions, anticholinergic agents will in-
crease the volume to the first involun-
tary bladder contraction, decrease the
amplitude of that contraction, increase
bladder capacity, but will not change the
“warning time”. Thus, drug therapy
must always be combined with
behavioral therapy to achieve optimal
results in OAB39.
The problem with current anticho-
linergics has been the incidence of side
effects, particularly related to salivary
gland secretion and bowel function,
which are significant enough to cause
the patient to discontinue taking the
medication. In one study, it was esti-
mated that only approximately 18% of
patients remained on anticholinergic
therapy for over 6 months48. Activation
of the M-3 receptors is responsible for
bladder contraction, but M-3 receptors
are also responsible for salivary gland
smooth muscle contraction and gut
smooth muscle contraction. Receptor
selectivity alone does not seem to be a
terribly practical concept for developing
new agents unless an agent preferen-
tially inhibits bladder M-3 receptors
over those of the salivary gland or gut.
Tolterodine is a recently introduced
agent that is not receptor specific but
that is relatively tissue-specific, in the
sense that it has a greater effect on blad-
der smooth muscle than on salivary
gland smooth muscle. Oxybutynin is the
most prescribed anticholinergic drug
and appears to have the opposite profile.
In trials to date, tolterodine has pro-
duced beneficial therapeutic effects
equivalent to oxybutynin with signifi-
cantly fewer adverse effects than cur-
rently used oxybutynin preparations49-51.
Reductions in OAB incontinence epi-
sodes with anticholinergic therapy range
from 40% to 70%, with reductions in
urinary frequency being statistically sig-
nificant but numerically less49-51.
Table 3 - Commonly utilized anticholinergic/antispasmodic preparations.
Anticholinergic agents Dose (adults)
Hyoscyamine sulfate (Levsin)* 0.125 mg 3-4x/day
Propantheline bromide (Probantine)** 7.5-30 mg 3-4x/day
Tolterodine (Detrusitol) 1-2 mg 2x/day
Antispasmodics (variable amounts of anticholinergic properties)
Oxybutinin chloride (Retemic, Incontinol, Urazol, Frenurin) 2.5-5 mg 3x/day
Oxybutinin chloride extended release (Ditropan XL)* 5-10 mg 1x/day
Dicyclomine hydrochloride (Bentyl) 10-20 mg 3x/day
Flavoxate hydrochloride (Genurin) 200 mg 3-4x/day
*Not available in Brasil
**Prepared under prescription in Brasil
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Estrogen therapy has the potential
for successful treatment of OAB symp-
tomatology in postmenopausal women.
Although there are multiple mecha-
nisms by which estrogen might
favorably affect lower urinary tract
function, opinion is divided as to
whether low dose local therapy or sys-
temic therapy can per se ameliorate ir-
ritative lower urinary tract symptoms in
the postmenopausal female52-55.
Peripheral electrical stimulation
Electrical stimulation has been used
by some investigators with success56-59.
Peripheral electrical stimulation is
thought to act through a mechanism
involving reflex inhibition of motor
output to the bladder and by activating
inhibitory sympathetic fibers. However,
there are disclaimers. Reported results
have been mostly in patients with ur-
gency incontinence, since incontinence
episodes are generally associated with
involuntary bladder contractions (a
measurable parameter) and since in-
continence episodes themselves are
relatively easy to quantitate. Vaginal,
anal, and lower extremity electrodes
have produced “cure” rates of as high
as 20% and improvement rates as high
as 50% to 60%56-59. Duration of
therapy, duration and intensity of
stimulus, ideal delivery modality, and
other parameters are not standardized
and vary considerably between institu-
tions. Often, in series such as these (not
just electrical stimulation), it is difficult
to figure out exactly what “improve-
ment” means, and for how long im-
provement lasts, and whether patients
believe that, overall, their quality of life
is significantly improved.
Other therapies
Bladder overdistention, transvagi-
nal alcohol/phenol injections, and
transvaginal dissection, such as the
Ingelman-Sundberg procedure, are all
forms of peripheral denervation/neuro-
logic decentralization. Each has its ad-
vocates. Following the progression of
the algorithm to this stage with unsuc-
cessful results, and excluding sacral
rhizotomy or dorsal ganglionectomy in
patients other than spinal cord injury
patients, the two modalities of therapy
that remain are an implantable
stimulator for neuromodulation and
augmentation cystoplasty. Catheteriza-
tion or urinary diversion can each be
thought of as methods for circumvent-
ing the condition, not treating it47.
Neuromodulation is a term used to
describe alteration of reflex pathways.
Sacral nerve stimulation with an
implantable stimulator has been used
with success for urge incontinence60-63.
This minimally invasive procedure is a
2-step process. Initially, the patient has
percutaneous placement of a wire elec-
trode into the S3 foramina alongside of
the nerve root as an outpatient proce-
dure. The wire is then attached to an
external pulse generator, and the pa-
tient is sent home. If the patient has a
suitable response after 3 days of
therapy, a permanent implant is then
scheduled. The surgery for the perma-
nent implant involves an incision in the
lower back with a wire advanced into
the S3 foramina under direct vision.
The wire is then tunneled around to the
flank. A pulse generator is then placed
into the subcutaneous tissues on the
anterior abdominal wall. The pulse
generator is connected to the previ-
ously placed wire as it is tunneled sub-
cutaneously around the flank. The
pulse generator can be programmed by
an external device and magnet in a
similar manner as for a cardiac pace-
maker. Trials are still ongoing with this
device (Interstim®) for urge inconti-
nence and other lower urinary tract
dysfunctions.
Surgery may improve severe
overactive bladder symptoms when
more conservative management has
failed. Augmentation cystoplasty refers
to procedures that increase bladder ca-
pacity. In enterocystoplasty, a portion
of bowel is removed from the fecal
stream and is incorporated into the
dome of the bladder. Thus, although
detrusor overactivity may remain, con-
tractions in the filling phase do not re-
sult in a rise in detrusor pressure suffi-
cient to cause leakage. However, sub-
sequent complications that may arise
include inadequate emptying resulting
in recurrent urinary tract infections,
urinary retention, mucous accumula-
tion and stones, electrolyte imbalance,
and rarely, malignant change. Not all
patients are candidates for augmenta-
tion cystoplasty, and the possibility of
the need for lifetime clean intermittent
catheterization must be discussed with
the patient prior to the consideration of
surgery. The potential complications
ensure that surgical procedures are re-
served for severe cases of urge incon-
tinence that have been resistant to con-
servative therapy64.
Auto-augmentation refers to a type
of cystoplasty that involves excision of
a large portion of detrusor muscle with
preservation of the underlying mucosa
(detrusor myomectomy). This proce-
dure allows a bladder diverticulum to
form with consequent increase in ca-
pacity64. The procedure avoids the mor-
bidity associated with bowel resection
and incorporation of bowel in the uri-
nary tract, but there is far from unani-
mous agreement that the results ap-
proach those of enterocystoplasty.
Potentially promising new therapies
are on the horizon for the OAB. Cur-
rently under development are a number
of pharmaceutical agents, including
monoamine reuptake inhibitors,
antimuscarinic agents, and intravesical
agents that decrease afferent input,
such as capsaicin and capsaicin-like
agents, which may herald a new thera-
peutic paradigm for treatment of the
OAB. Refinements in the technique
and the delivery vehicle for electrical
stimulation may offer an even less in-
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vasive method of neuromodulation. Fi-
nally, ongoing research in biotechnol-
ogy and tissue engineering may pro-
duce a functional, stable, compatible
tissue substitute suitable for bladder
augmentation that is produced entirely
in the laboratory, thereby precluding
the need for bowel interposition in the
urinary tract and its attendant morbid-
ity65-70.
RESUMO RHCFAP/3067
ROVNER ES e col. - Avaliação e
tratamento da bexiga hiperativa.
Rev. Hosp. Clín. Fac. Med. S.
Paulo 57(1):39-48, 2002.
A bexiga hiperativa é caracterizada
pelos sintomas de freqüência, urgência
e urge-incontinência e afeta de forma
significativa o estilo de vida de milhões
de pessoas em todo o mundo. Os sin-
tomas são responsáveis por problemas
nas esferas social, psicológica, ocupa-
cional, doméstica, física e sexual dos
pacientes. Apesar do considerável im-
pacto desta condição sobre a qualida-
de de vida, grande parte dos pacientes
reluta em discutir o problema com
membros da família ou profissionais de
saúde. Esta situação é lamentável, já
que existem muitas maneiras de aliviar
os sintomas da hiperatividade vesical.
Por essa razão, é fundamental que se
aprimore a educação médica sobre os
sintomas de hiperatividade vesical e
outros problemas relacionados, de
modo a preparar os profissionais de
saúde a identificar e tratar os pacien-
tes com esta condição. Este artigo é
uma revisão dos conceitos atuais, de-
finição, epidemiologia, efeitos sobre a
qualidade de vida, avaliação e trata-
mento da bexiga hiperativa.
DESCRITORES: Bexiga. Inconti-
nência urinária. Urodinâmica.
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